	US 12,491,156 B2
	Carrier particles for dry powder formulations for inhalation
Tomaso Guidi, Parma (IT); and Andrea Benassi, Parma (IT)
Assigned to CHIESI FARMACEUTICI S.P.A., Parma (IT)
Appl. No. 17/763,595
Filed by Chiesi Farmaceutici S.p.A., Parma (IT)
PCT Filed Sep. 22, 2020, PCT No. PCT/EP2020/076369 § 371(c)(1), (2) Date Mar. 24, 2022, PCT Pub. No. WO2021/058454, PCT Pub. Date Apr. 1, 2021.
Claims priority of application No. 19199337 (EP), filed on Sep. 24, 2019.
Prior Publication US 2022/0331244 A1, Oct. 20, 2022
Int. Cl. A61K 9/00 (2006.01); A61K 31/573 (2006.01); A61K 47/26 (2006.01)

CPC A61K 9/0075 (2013.01) [A61K 31/573 (2013.01); A61K 47/26 (2013.01)]

18 Claims

1. A dry powder formulation for administration by a dry powder inhaler (DPI) comprising:

a) a fraction of spheronised particles having a mass diameter comprised between 100 and 800 micrometers comprising micronized particles of one or more active ingredients and micronized particles of a physiologically acceptable excipient;

b) a fraction of coarse particles comprising a physiologically acceptable excipient having a mass diameter comprised between 150 and 400 micrometers;

wherein the ratio between the fraction a) and the fraction b) is comprised between 5:95 and 50:50 percent by weight.